Biblio
“Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment.”, Neuron, vol. 74, no. 3, pp. 467-74, 2012.
, “Designing an Internet-Based Multidomain Intervention for the Prevention of Cardiovascular Disease and Cognitive Impairment in Older Adults: The HATICE Trial.”, J Alzheimers Dis, vol. 62, no. 2, pp. 649-663, 2018.
, “The Progression of Alzheimer's Disease: Are Fast Decliners Really Fast? A Four-Year Follow-Up.”, J Alzheimers Dis, vol. 57, no. 3, pp. 775-786, 2017.
, “Differential Mass Spectrometry Profiles of Tau Protein in the Cerebrospinal Fluid of Patients with Alzheimer's Disease, Progressive Supranuclear Palsy, and Dementia with Lewy Bodies.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1033-43, 2016.
, “Dementia Care in Times of COVID-19: Experience at Fundació ACE in Barcelona, Spain.”, J Alzheimers Dis, vol. 76, no. 1, pp. 33-40, 2020.
, “Performance on Specific Cognitive Domains and Cause of Death: A Prospective Population-Based Study in Non-Demented Older Adults (NEDICES).”, J Alzheimers Dis, vol. 51, no. 2, pp. 533-44, 2016.
, “Safety and Tolerability of R(+) Pramipexole in Mild-to-Moderate Alzheimer's Disease.”, J Alzheimers Dis, vol. 49, no. 4, pp. 1179-87, 2016.
, “Associations between Neuropsychiatric Symptoms and Cerebral Amyloid Deposition in Cognitively Impaired Elderly People.”, J Alzheimers Dis, vol. 49, no. 2, pp. 387-98, 2016.
, “Effect of Tween-20 on Core Biomarkers Measured in Cerebrospinal Fluid from Patients with Alzheimer's Disease, Mild Cognitive Impairment, or Healthy Control Individuals.”, J Alzheimers Dis, vol. 49, no. 2, pp. 493-502, 2016.
, “APOE4 Copy Number-Dependent Proteomic Changes in the Cerebrospinal Fluid.”, J Alzheimers Dis, vol. 79, no. 2, pp. 511-530, 2021.
, “Clinical Impact of a Second FDG-PET in Atypical/Unclear Dementia Syndromes.”, J Alzheimers Dis, vol. 49, no. 3, pp. 695-705, 2016.
, “Prognostic Significance of Mild Cognitive Impairment Subtypes for Dementia and Mortality: Data from the NEDICES Cohort.”, J Alzheimers Dis, vol. 50, no. 3, pp. 719-31, 2016.
, “Neuronal activity regulates the regional vulnerability to amyloid-β deposition.”, Nat Neurosci, vol. 14, no. 6, pp. 750-6, 2011.
, “Social Cognition Deficits: The Key to Discriminate Behavioral Variant Frontotemporal Dementia from Alzheimer's Disease Regardless of Amnesia?”, J Alzheimers Dis, vol. 49, no. 4, pp. 1065-74, 2016.
, “Trends, Predictors, and Outcomes of Healthcare Resources Used in Patients Hospitalized with Alzheimer's Disease with at Least One Procedure: The Nationwide Inpatient Sample.”, J Alzheimers Dis, vol. 57, no. 3, pp. 813-824, 2017.
, “ANMerge: A Comprehensive and Accessible Alzheimer's Disease Patient-Level Dataset.”, J Alzheimers Dis, vol. 79, no. 1, pp. 423-431, 2021.
, “Comparative Cognitive Effects of Choreographed Exercise and Multimodal Physical Therapy in Older Adults with Amnestic Mild Cognitive Impairment: Randomized Clinical Trial.”, J Alzheimers Dis, vol. 73, no. 2, pp. 769-783, 2020.
, “Cerebrospinal Fluid Fatty Acid-Binding Protein 3 is Related to Dementia Development in a Population-Based Sample of Older Adult Women Followed for 8 Years.”, J Alzheimers Dis, vol. 49, no. 3, pp. 733-41, 2016.
, “Economic Burden, Mortality, and Institutionalization in Patients Newly Diagnosed with Alzheimer's Disease.”, J Alzheimers Dis, vol. 61, no. 1, pp. 185-193, 2018.
, “Genetic Counseling and Testing for Alzheimer's Disease and Frontotemporal Lobar Degeneration: An Italian Consensus Protocol.”, J Alzheimers Dis, vol. 51, no. 1, pp. 277-91, 2016.
, “Clearing Amyloid-β through PPARγ/ApoE Activation by Genistein is a Treatment of Experimental Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 3, pp. 701-11, 2016.
, “Neuropsychiatric Symptoms in Patients with Dementia Associated with Increased Psychological Distress in Caregivers During the COVID-19 Pandemic.”, J Alzheimers Dis, vol. 80, no. 4, pp. 1705-1712, 2021.
, “Different Inflammatory Signatures in Alzheimer's Disease and Frontotemporal Dementia Cerebrospinal Fluid.”, J Alzheimers Dis, vol. 81, no. 2, pp. 629-640, 2021.
, “Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1069-83, 2016.
, “The Effects of Confinement on Neuropsychiatric Symptoms in Alzheimer's Disease During the COVID-19 Crisis.”, J Alzheimers Dis, vol. 76, no. 1, pp. 41-47, 2020.
,